Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

[1]  QUAN LIU,et al.  Macrophages in immunoregulation and therapeutics , 2023, Signal transduction and targeted therapy.

[2]  Y. Tao,et al.  Signaling pathways in cancer metabolism: mechanisms and therapeutic targets , 2023, Signal transduction and targeted therapy.

[3]  Wei Wang,et al.  LncTUG1 contributes to the progression of hepatocellular carcinoma via the miR-144-3p/RRAGD axis and mTOR/S6K pathway , 2023, Scientific reports.

[4]  Matthew D. Dun,et al.  ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma , 2023, Cancer research.

[5]  E. Gordon,et al.  A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway , 2023, AntiCancer Research.

[6]  K. Kotulska,et al.  Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age , 2023, Neurology and Therapy.

[7]  Y. Liu,et al.  Genome-wide CRISPR screens identify ILF3 as a mediator of mTORC1-dependent amino acid sensing , 2023, Nature Cell Biology.

[8]  T. Ganesan,et al.  Long non-coding RNAs: Fundamental regulators and emerging targets of cancer stem cells. , 2023, Biochimica et biophysica acta. Reviews on cancer.

[9]  M. Tambuwala,et al.  Role of mammalian target of rapamycin (mTOR) signalling in oncogenesis. , 2023, Life sciences.

[10]  Mi-Hyeon Jeong,et al.  Regulation of mTORC1 by the Rag GTPases , 2023, Biochemical Society transactions.

[11]  R. Glasspool,et al.  Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial. , 2023, JAMA oncology.

[12]  Jin-zhuo Ning,et al.  Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages , 2023, Heliyon.

[13]  J. Hurley,et al.  Amino acid sensing and lysosomal signaling complexes. , 2023, Current opinion in structural biology.

[14]  T. Sargeant,et al.  Rapamycin and Alzheimer disease: a hypothesis for the effective use of rapamycin for treatment of neurodegenerative disease , 2023, Autophagy.

[15]  Wenyi Wei,et al.  AMPK-dependent phosphorylation of the GATOR2 component WDR24 suppresses glucose-mediated mTORC1 activation , 2023, Nature Metabolism.

[16]  Yunbo Shi,et al.  Amino acid transporter SLC7A5 regulates Paneth cell function to affect the intestinal inflammatory response , 2023, bioRxiv.

[17]  Wenyi Wei,et al.  Ring domains are essential for GATOR2-dependent mTORC1 activation. , 2022, Molecular cell.

[18]  S. Roychoudhury,et al.  Transition of amyloid/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness , 2022, Cancer Cell International.

[19]  G. Lenz,et al.  mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma , 2022, Leukemia.

[20]  K. Gelmon,et al.  A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer , 2022, British Journal of Cancer.

[21]  Małgorzata Wieteska,et al.  New Directions in the Therapy of Glioblastoma , 2022, Cancers.

[22]  J. Sharifi‐Rad,et al.  Recent advances and limitations of mTOR inhibitors in the treatment of cancer , 2022, Cancer Cell International.

[23]  É. Vivier,et al.  Bringing natural killer cells to the clinic , 2022, The Journal of experimental medicine.

[24]  S. Horvath,et al.  Rapamycin treatment during development extends life span and health span of male mice and Daphnia magna , 2022, Science advances.

[25]  P. Dakle,et al.  Transcriptome analysis identifies TODL as a novel lncRNA associated with proliferation, differentiation, and tumorigenesis in liposarcoma through FOXM1 Running Title: TODL lncRNA as a potential therapeutic target for liposarcoma. , 2022, Pharmacological research.

[26]  A. Uysal,et al.  Voxtalisib and low intensity pulsed ultrasound combinatorial effect on glioblastoma multiforme cancer stem cells via PI3K/AKT/mTOR. , 2022, Pathology, research and practice.

[27]  Guanya Li,et al.  The central role of mTORC1 in amino acid sensing. , 2022, Cancer research.

[28]  Yundong He,et al.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials , 2022, Signal Transduction and Targeted Therapy.

[29]  T. Ganesan,et al.  Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade , 2022, Cellular and Molecular Life Sciences.

[30]  Jianyou Shi,et al.  Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment , 2022, Frontiers in Pharmacology.

[31]  A. Woywodt,et al.  A treasure from a barren island: the discovery of rapamycin , 2022, Clinical kidney journal.

[32]  M. S. Mukhtar,et al.  Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism , 2022, Molecular carcinogenesis.

[33]  G. Calin,et al.  Targeting non-coding RNAs to overcome cancer therapy resistance , 2022, Signal Transduction and Targeted Therapy.

[34]  J. Krell,et al.  DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment—a study protocol for a randomised trial investigating a novel therapy called TAK228 , 2022, Trials.

[35]  Zhan-Ju Liu,et al.  OSI‐027 inhibits the tumorigenesis of colon cancer through mediation of c‐Myc/FOXO3a/PUMA axis , 2022, Cell biology international.

[36]  W. Cho,et al.  mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment , 2022, Frontiers in Immunology.

[37]  M. Sulis,et al.  Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001) , 2022, Haematologica.

[38]  Kui-Sheng Chen,et al.  Targeting PI3K/Akt signal transduction for cancer therapy , 2021, Signal Transduction and Targeted Therapy.

[39]  T. Weichhart,et al.  p38 regulates the tumor suppressor PDCD4 via the TSC-mTORC1 pathway , 2021, Cell stress.

[40]  P. Wang,et al.  Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines , 2021, Cells.

[41]  E. Jabłońska,et al.  Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells , 2021, International journal of molecular sciences.

[42]  Rony Cohen,et al.  Behavioral Symptoms May Correlate With the Load and Spatial Location of Tubers and With Radial Migration Lines in Tuberous Sclerosis Complex , 2021, Frontiers in Neurology.

[43]  D. Kwiatkowski,et al.  nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Ashrafizadeh,et al.  Long noncoding RNAs: A novel insight in the leukemogenesis and drug resistance in acute myeloid leukemia , 2021, Journal of cellular physiology.

[45]  P. Wangikar,et al.  Transporter engineering for the development of cyanobacteria as cell factories: A text analytics guided survey. , 2021, Biotechnology advances.

[46]  Xia-Wei Wei,et al.  Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[47]  Ayushi Sharma,et al.  Long non-coding RNAs orchestrate various molecular and cellular processes by modulating epithelial-mesenchymal transition in head and neck squamous cell carcinoma. , 2021, Biochimica et biophysica acta. Molecular basis of disease.

[48]  T. Ganesan,et al.  Development and in vitro characterisation of an induced pluripotent stem cell model of ovarian cancer. , 2021, The international journal of biochemistry & cell biology.

[49]  Jiahua Yu,et al.  The PI3K/mTOR Inhibitor Ompalisib Suppresses Nonhomologous End Joining and Sensitizes Cancer Cells to Radio- and Chemotherapy , 2021, Molecular Cancer Research.

[50]  A. Stathis,et al.  Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors , 2021, Clinical Cancer Research.

[51]  A. Efeyan,et al.  The mTOR–Autophagy Axis and the Control of Metabolism , 2021, Frontiers in Cell and Developmental Biology.

[52]  G. Sethi,et al.  "Emerging role of long non-coding RNA (lncRNA) in human malignancies: A unique opportunity for precision medicine". , 2021, Cancer letters.

[53]  A. Atapour,et al.  The emerging role of microRNA in regulating the mTOR signaling pathway in immune and inflammatory responses , 2021, Immunology and cell biology.

[54]  S. Gygi,et al.  mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events , 2021, Cell.

[55]  M. Pavlyukov,et al.  LncRNAs associated with glioblastoma: From transcriptional noise to novel regulators with a promising role in therapeutics , 2021, Molecular therapy. Nucleic acids.

[56]  Jianguo Wang,et al.  Targeting tumor-associated macrophages to synergize tumor immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[57]  T. Si,et al.  ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells , 2021, Cancer cell international.

[58]  M. Jücker,et al.  The Role of mTOR Signaling as a Therapeutic Target in Cancer , 2021, International journal of molecular sciences.

[59]  L. Platanias,et al.  Combined PI3Kα-mTOR Targeting of Glioma Stem Cells , 2020, Scientific Reports.

[60]  Yin Lu,et al.  Critical role of mTOR in regulating aerobic glycolysis in carcinogenesis (Review). , 2020, International journal of oncology.

[61]  Hao Zhu,et al.  OSI-027 alleviates oxaliplatin chemoresistance in gastric cancer cells by suppressing P-gp induction. , 2020, Current molecular medicine.

[62]  B. Goh,et al.  The double-edged sword of H19 lncRNA: Insights into cancer therapy. , 2020, Cancer letters.

[63]  Y. Dou,et al.  ER associated degradation preserves hematopoietic stem cell quiescence and self-renewal by restricting mTOR activity. , 2020, Blood.

[64]  D. Calvisi,et al.  Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma , 2020, Gut.

[65]  S. Cherry,et al.  Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. , 2020, Clinical lung cancer.

[66]  David C. Smith,et al.  Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer , 2020, British Journal of Cancer.

[67]  S. H. Lee,et al.  GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway. , 2020, Biochemical and biophysical research communications.

[68]  G. Sethi,et al.  The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[69]  T. Hung,et al.  Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. , 2020, Biochemical pharmacology.

[70]  Xianqun Fan,et al.  ZNNT1 long noncoding RNA induces autophagy to inhibit tumorigenesis of uveal melanoma by regulating key autophagy gene expression , 2020, Autophagy.

[71]  Xiangdong Xue,et al.  Novel Nanococktail of a Dual PI3K/mTOR Inhibitor and Cabazitaxel for Castration‐Resistant Prostate Cancer , 2020, Advanced therapeutics.

[72]  Aklank Jain,et al.  Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: Enusage of plasticity , 2020, Annals of translational medicine.

[73]  T. Ganesan,et al.  The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary , 2020, Cellular Oncology.

[74]  G. Sethi,et al.  Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics. , 2020, Seminars in cancer biology.

[75]  M. Hall,et al.  The 3.2-Å resolution structure of human mTORC2 , 2020, Science Advances.

[76]  P. Wen,et al.  Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma , 2020, Clinical Cancer Research.

[77]  Tao Tao,et al.  mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges , 2020, Cell & Bioscience.

[78]  G. Sethi,et al.  Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy. , 2020, Seminars in cancer biology.

[79]  Wen Peng,et al.  Targeting cancer stem cell pathways for cancer therapy , 2020, Signal Transduction and Targeted Therapy.

[80]  D. Allman,et al.  mTORC1 coordinates an immediate unfolded protein response-related transcriptome in activated B cells preceding antibody secretion , 2020, Nature Communications.

[81]  P. Wen,et al.  First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma , 2020, Clinical Cancer Research.

[82]  Everolimus , 2020, Reactions Weekly.

[83]  D. Provencher,et al.  EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. , 2019, Gynecologic oncology.

[84]  E. Jacinto,et al.  Targeting mTOR and Metabolism in Cancer: Lessons and Innovations , 2019, Cells.

[85]  K. Aboudehen,et al.  Regulation of mTOR signaling by long non-coding RNA. , 2019, Biochimica et biophysica acta. Gene regulatory mechanisms.

[86]  B. Fiebich,et al.  NVP-BEZ235 (Dactolisib) Has Protective Effects in a Transgenic Mouse Model of Alzheimer’s Disease , 2019, Front. Pharmacol..

[87]  F. Wondisford,et al.  Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK , 2019, Cell reports.

[88]  C. Arteaga,et al.  Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer? , 2019, JAMA oncology.

[89]  G. Sethi,et al.  Engineering anti-cancer nanovaccine based on antigen cross-presentation , 2019, Bioscience reports.

[90]  J. Nemunaitis,et al.  A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms , 2019, PloS one.

[91]  A. K. Murugan.  mTOR: Role in cancer, metastasis and drug resistance. , 2019, Seminars in cancer biology.

[92]  H. Hua,et al.  Targeting mTOR for cancer therapy , 2019, Journal of Hematology & Oncology.

[93]  Ø. Bruserud,et al.  Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells , 2019, Signal Transduction and Targeted Therapy.

[94]  F. Rojo,et al.  Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models , 2019, Molecular Cancer Research.

[95]  Alexandra G. Smith,et al.  Autophagy, cancer stem cells and drug resistance , 2019, The Journal of pathology.

[96]  Li Wu,et al.  Metabolic Regulation of Dendritic Cell Differentiation , 2019, Front. Immunol..

[97]  Yuquan Wei,et al.  Targeting PI3K in cancer: mechanisms and advances in clinical trials , 2019, Molecular Cancer.

[98]  D. Dittmer,et al.  Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma , 2019, mBio.

[99]  R. Chambers,et al.  A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis , 2019, European Respiratory Journal.

[100]  Jinhua Zhang,et al.  mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy , 2019, International journal of molecular sciences.

[101]  Kai Yang,et al.  Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma , 2019, Cell Death & Disease.

[102]  Xiefu Zhang,et al.  Overexpression of long noncoding RNA GAS5 suppresses tumorigenesis and development of gastric cancer by sponging miR-106a-5p through the Akt/mTOR pathway , 2019, Biology Open.

[103]  J. Avruch.  Faculty Opinions recommendation of 4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[104]  M. Newton,et al.  MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers , 2018, Molecular Cancer Therapeutics.

[105]  P. Barata,et al.  Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer , 2018, Investigational New Drugs.

[106]  W. Rui,et al.  Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours , 2018, Nature Communications.

[107]  Xiaohui Li,et al.  Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function , 2018, Nature Communications.

[108]  Xiao-Bing Chen,et al.  Long noncoding RNA growth arrest‐specific 5 facilitates glioma cell sensitivity to cisplatin by suppressing excessive autophagy in an mTOR‐dependent manner , 2018, Journal of cellular biochemistry.

[109]  T. Hsia,et al.  The Contribution of MMP-7 Promoter Polymorphisms to Taiwan Lung Cancer Susceptibility , 2018, AntiCancer Research.

[110]  Xiao Fu,et al.  Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy , 2018, Cancer science.

[111]  Zena Werb,et al.  Roles of the immune system in cancer: from tumor initiation to metastatic progression , 2018, Genes & development.

[112]  E. Nakakura,et al.  A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors , 2018, Molecular Cancer Therapeutics.

[113]  Yao Liu,et al.  lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR , 2018, Molecular carcinogenesis.

[114]  J. O’Shaughnessy,et al.  Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer. , 2018, Cancer treatment reviews.

[115]  P. Houghton,et al.  ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer , 2018, Science Advances.

[116]  M. Beibel,et al.  TORC1 inhibition enhances immune function and reduces infections in the elderly , 2018, Science Translational Medicine.

[117]  J. Kattan,et al.  RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer. , 2018, Pharmacogenomics.

[118]  S. Malarkannan,et al.  mTORC1 and mTORC2 differentially promote natural killer cell development , 2018, eLife.

[119]  Thomas D. Schmittgen,et al.  CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128 , 2018, Oncotarget.

[120]  R. Jensen,et al.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence , 2018, Expert opinion on pharmacotherapy.

[121]  K. Hunter,et al.  Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence , 2018, Nature Communications.

[122]  M. Tajimi,et al.  PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay , 2018, Japanese journal of clinical oncology.

[123]  M. Kersten,et al.  Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. , 2018, The Lancet. Haematology.

[124]  Junmin Li,et al.  Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways , 2018, Journal of Experimental & Clinical Cancer Research.

[125]  B. Jiang,et al.  Long noncoding RNAs in the mTOR signaling network: biomarkers and therapeutic targets , 2018, Apoptosis.

[126]  H. Scher,et al.  A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer , 2018, Investigational New Drugs.

[127]  J. Guan,et al.  AMPK Inhibits ULK1-Dependent Autophagosome Formation and Lysosomal Acidification via Distinct Mechanisms , 2018, Molecular and Cellular Biology.

[128]  Yun Chen,et al.  AZD8055 Exerts Antitumor Effects on Colon Cancer Cells by Inhibiting mTOR and Cell-cycle Progression. , 2018, Anticancer research.

[129]  Xiao-Feng Li,et al.  CC-223 inhibits human head and neck squamous cell carcinoma cell growth. , 2018, Biochemical and biophysical research communications.

[130]  R. Neuwirth,et al.  Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours , 2018, ESMO Open.

[131]  P. LoRusso,et al.  A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors , 2018, Investigational New Drugs.

[132]  S. K. R. Guduru,et al.  Synthesis and biological evaluation of rapamycin-derived, next generation small molecules. , 2018, MedChemComm.

[133]  Rui Xia,et al.  STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy , 2018, Molecular Cancer.

[134]  M. Milella,et al.  mTOR Cross-Talk in Cancer and Potential for Combination Therapy , 2018, Cancers.

[135]  Elsje G. Otten,et al.  mTORC1 as the main gateway to autophagy , 2017, Essays in biochemistry.

[136]  D. Calvisi,et al.  Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. , 2017, Journal of hepatology.

[137]  Jennifer M. A. Tullet,et al.  RNA polymerase III limits longevity downstream of TORC1 , 2017, Nature.

[138]  J. Tyner,et al.  Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets , 2017, Journal of Hematology & Oncology.

[139]  Xianghuo He,et al.  MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway. , 2017, Cancer research.

[140]  J. Tabernero,et al.  A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer , 2017, Targeted Oncology.

[141]  D. Fabbro,et al.  PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy , 2017, Clinical Cancer Research.

[142]  I. Martinez-Argudo,et al.  Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. , 2017, Cancer letters.

[143]  T. Weichhart,et al.  mTORC1 and mTORC2 as regulators of cell metabolism in immunity , 2017, FEBS letters.

[144]  H. Ruohola-Baker,et al.  Loss of foxo rescues stem cell aging in Drosophila germ line , 2017, eLife.

[145]  J. Mestan,et al.  5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. , 2017, Journal of medicinal chemistry.

[146]  N. Foster,et al.  Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. , 2017, Gynecologic oncology.

[147]  T. Hung,et al.  Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells. , 2017, Molecular pharmaceutics.

[148]  Lovelace J. Luquette,et al.  A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. , 2017, Cancer cell.

[149]  N. Nikitakis.  Glimpses of the near future: a new generation of mTOR inhibitors. , 2017, Oral diseases.

[150]  B. Iritani,et al.  Control of B lymphocyte development and functions by the mTOR signaling pathways. , 2017, Cytokine & growth factor reviews.

[151]  Aijun Yang,et al.  Preclinical study of CC223 as a potential anti-ovarian cancer agent , 2017, Oncotarget.

[152]  B. Mellado,et al.  Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. , 2017, European journal of cancer.

[153]  D. Teachey,et al.  A phase 1 trial of temsirolimus and intensive re‐induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114) , 2017, British journal of haematology.

[154]  Zichen Xie,et al.  CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo , 2017, PloS one.

[155]  Erin F. Simonds,et al.  A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. , 2017, Cancer cell.

[156]  David M. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[157]  H. Benyamini,et al.  Long Noncoding RNA MALAT1 Promotes Hepatocellular Carcinoma Development by SRSF1 Upregulation and mTOR Activation. , 2017, Cancer research.

[158]  R. DePinho,et al.  Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer , 2017, Nature.

[159]  Gu,et al.  KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1 , 2017, Nature.

[160]  D. Klionsky,et al.  Autophagy wins the 2016 Nobel Prize in Physiology or Medicine: Breakthroughs in baker's yeast fuel advances in biomedical research , 2016, Proceedings of the National Academy of Sciences.

[161]  Akinobu Matsumoto,et al.  mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide , 2016, Nature.

[162]  Mengjie Liu,et al.  4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1 , 2016, Protein & Cell.

[163]  H. Morreau,et al.  Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial , 2016, The Journal of clinical endocrinology and metabolism.

[164]  T. Weichhart,et al.  mTOR-Mediated Regulation of Dendritic Cell Differentiation and Function. , 2016, Trends in immunology.

[165]  Sara M. Federico,et al.  A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors , 2016, Oncotarget.

[166]  P. LoRusso.  Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[167]  J. Beijnen,et al.  PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models , 2016, Clinical Cancer Research.

[168]  Dana M. Brantley-Sieders,et al.  Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. , 2016, Cancer research.

[169]  P. Iversen,et al.  Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth , 2016, Molecular Cancer Therapeutics.

[170]  M. Berger,et al.  Abstract 2147: Overcoming mTOR resistance mutations with a new generation mTOR inhibitor , 2016 .

[171]  Sara M. Federico,et al.  Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. , 2016, European journal of cancer.

[172]  Craig B. Davis,et al.  A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. , 2016, Gynecologic oncology.

[173]  Tao Luo,et al.  PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression , 2016, Autophagy.

[174]  Dudley Lamming.  Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond. , 2016, Cold Spring Harbor perspectives in medicine.

[175]  B. Iritani,et al.  Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism , 2016, The Journal of Immunology.

[176]  Erika Ilagan,et al.  Emerging role of mTOR in the response to cancer therapeutics. , 2016, Trends in cancer.

[177]  Christopher M Johnson,et al.  Tor forms a dimer through an N-terminal helical solenoid with a complex topology , 2016, Nature Communications.

[178]  James C Yao,et al.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study , 2016, The Lancet.

[179]  T. Park-Simon,et al.  Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). , 2016, Gynecologic oncology.

[180]  S. Sundar,et al.  A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. , 2016, European urology.

[181]  Kun Li,et al.  Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression , 2016, Acta Pharmacologica Sinica.

[182]  Jing Wang,et al.  lncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress , 2016, Nature Cell Biology.

[183]  Ping Yang,et al.  HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas , 2016, Oncotarget.

[184]  K. Guan,et al.  Structural insights of mTOR complex 1 , 2016, Cell Research.

[185]  M. Zauderer,et al.  Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.

[186]  D. Sabatini,et al.  Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway , 2016, Science.

[187]  Shu Liu,et al.  mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR , 2015, Cell Research.

[188]  C. Thompson,et al.  GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2 , 2015, Genes & development.

[189]  J. Blenis,et al.  PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. , 2015, Cancer discovery.

[190]  Yunliang Wang,et al.  CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. , 2015, Cancer letters.

[191]  S. A. Arriola Apelo,et al.  Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system , 2015, Aging cell.

[192]  Gang Zhao,et al.  NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. , 2015, Cancer letters.

[193]  Hui Zhang,et al.  The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2. , 2015, DNA and cell biology.

[194]  Sanjay Goel,et al.  RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. , 2015, Cancer discovery.

[195]  P. Wen,et al.  Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. , 2015, Neuro-oncology.

[196]  David E James,et al.  A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation. , 2015, Cell reports.

[197]  A. Armstrong,et al.  A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma. , 2015, Clinical genitourinary cancer.

[198]  T. Liang,et al.  OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo , 2015, Oncotarget.

[199]  M. Ikura,et al.  Point mutations of the mTOR-RHEB pathway in renal cell carcinoma , 2015, Oncotarget.

[200]  E. Thiry,et al.  Something old, something new , 2015, Journal of feline medicine and surgery.

[201]  A. Oza,et al.  Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[202]  D. Raggi,et al.  Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma , 2015, Therapeutic advances in urology.

[203]  C. Behrends,et al.  Amino Acid-Dependent mTORC1 Regulation by the Lysosomal Membrane Protein SLC38A9 , 2015, Molecular and Cellular Biology.

[204]  Greg M. Delgoffe,et al.  mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation. , 2015, The Journal of clinical investigation.

[205]  J. Dering,et al.  In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response , 2015, Breast Cancer Research and Treatment.

[206]  G. Shapiro,et al.  First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer , 2015, Clinical Cancer Research.

[207]  Katherine H. Schreiber,et al.  Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins , 2015, Aging cell.

[208]  S. Ogawa,et al.  Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft. , 2015, The Journal of clinical endocrinology and metabolism.

[209]  B. Melichar,et al.  Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer. , 2015, Clinical breast cancer.

[210]  J. McCubrey,et al.  Current treatment strategies for inhibiting mTOR in cancer. , 2015, Trends in pharmacological sciences.

[211]  K. Guan,et al.  Differential regulation of mTORC1 by leucine and glutamine , 2015, Science.

[212]  K. Guan,et al.  mTOR: a pharmacologic target for autophagy regulation. , 2015, The Journal of clinical investigation.

[213]  J. Praestgaard,et al.  mTOR inhibition improves immune function in the elderly , 2014, Science Translational Medicine.

[214]  Elisa de Stanchina,et al.  MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma , 2014, Molecular Cancer Therapeutics.

[215]  D. Xiao,et al.  Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma , 2014, Molecular Cancer Therapeutics.

[216]  Wei Wang,et al.  Sestrins inhibit mTORC1 kinase activation through the GATOR complex. , 2014, Cell reports.

[217]  J. Lipton,et al.  The Neurology of mTOR , 2014, Neuron.

[218]  Nikhil Wagle,et al.  Response and acquired resistance to everolimus in anaplastic thyroid cancer. , 2014, The New England journal of medicine.

[219]  James B. Mitchell,et al.  Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384 , 2014, Clinical Cancer Research.

[220]  G. Braunstein,et al.  LAMC2 as a therapeutic target for cancers , 2014, Expert opinion on therapeutic targets.

[221]  G. Mills,et al.  Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors , 2014, Oncotarget.

[222]  B. Liu,et al.  Rictor Is Required for Early B Cell Development in Bone Marrow , 2014, PloS one.

[223]  Mei Xue,et al.  Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR–STAT3/microRNA143 pathway , 2014, Cancer science.

[224]  D. Moon,et al.  Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. , 2014, Anticancer research.

[225]  P. Codogno,et al.  Regulation of autophagy by amino acids and MTOR-dependent signal transduction , 2014, Amino Acids.

[226]  T. Wood,et al.  Conditional Ablation of Raptor or Rictor Has Differential Impact on Oligodendrocyte Differentiation and CNS Myelination , 2014, The Journal of Neuroscience.

[227]  Andrew H. Beck,et al.  A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. , 2014, Cancer discovery.

[228]  L. Cantley,et al.  Spatial Control of the TSC Complex Integrates Insulin and Nutrient Regulation of mTORC1 at the Lysosome , 2014, Cell.

[229]  S. Austad,et al.  Rapamycin extends life and health in C57BL/6 mice. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[230]  Mayumi Horie,et al.  Branched Chain Amino Acid Suppresses Hepatocellular Cancer Stem Cells through the Activation of Mammalian Target of Rapamycin , 2013, PloS one.

[231]  Dudley Lamming,et al.  The TSC-mTOR pathway regulates macrophage polarization , 2013, Nature Communications.

[232]  Qiang Li,et al.  The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. , 2013, Biochemical and biophysical research communications.

[233]  F. Mahon,et al.  PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor , 2013, Cell Death and Disease.

[234]  S. Ferguson,et al.  Recruitment of folliculin to lysosomes supports the amino acid–dependent activation of Rag GTPases , 2013, The Journal of cell biology.

[235]  E. Cuyás,et al.  Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway , 2013, Cell cycle.

[236]  A. Tinker,et al.  Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). , 2013, Gynecologic oncology.

[237]  G. Gores,et al.  The mTOR pathway in hepatic malignancies , 2013, Hepatology.

[238]  J. Blay,et al.  Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[239]  Q. Zhong,et al.  ULK1 targets Beclin-1 in autophagy , 2013, Nature Cell Biology.

[240]  T. P. Neufeld,et al.  ULK1 induces autophagy by phosphorylating Beclin-1 and activating Vps34 lipid kinase , 2013, Nature Cell Biology.

[241]  Jyh‐cherng Yu,et al.  The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors , 2013, Breast Cancer Research.

[242]  N. Pavletich,et al.  mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain , 2013, Nature.

[243]  Matthew Meyerson,et al.  A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1 , 2013, Science.

[244]  A. LaCasce,et al.  Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma , 2013, Haematologica.

[245]  U. Sauer,et al.  Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis , 2013, Science.

[246]  J. Asara,et al.  Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1 , 2013, Science.

[247]  J. Jung,et al.  Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells , 2013, Oncogene.

[248]  A. D’Assoro,et al.  Exploring new frontiers: sirolimus as a pharmacokinetic modulator in advanced cancer patients , 2013, Expert review of anticancer therapy.

[249]  O. Kirak,et al.  Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival , 2012, Nature.

[250]  G. Sledge,et al.  Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models , 2012, Breast Cancer Research and Treatment.

[251]  D. Sabatini,et al.  Ragulator Is a GEF for the Rag GTPases that Signal Amino Acid Levels to mTORC1 , 2012, Cell.

[252]  Irah L. King,et al.  Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice , 2012, The Journal of Immunology.

[253]  E. Raymond,et al.  Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma , 2012, British Journal of Cancer.

[254]  M. Maitland,et al.  Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients , 2012, Clinical Cancer Research.

[255]  T. Soga,et al.  mTORC1 is essential for leukemia propagation but not stem cell self-renewal. , 2012, The Journal of clinical investigation.

[256]  J. Tamburini,et al.  The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia , 2012, Leukemia.

[257]  Dudley Lamming,et al.  mTORC1 in the Paneth cell niche couples intestinal stem cell function to calorie intake , 2012, Nature.

[258]  Kira Glover-Cutter,et al.  TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. , 2012, Cell metabolism.

[259]  Hongbo Chi,et al.  Regulation and function of mTOR signalling in T cell fate decisions , 2012, Nature Reviews Immunology.

[260]  D. Sabatini,et al.  A unifying model for mTORC1-mediated regulation of mRNA translation , 2012, Nature.

[261]  R. Motzer,et al.  Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma , 2012, Cancer.

[262]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[263]  Dudley Lamming,et al.  Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity , 2012, Science.

[264]  Nicholas T. Ingolia,et al.  The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.

[265]  P. Soares,et al.  The mTOR Signalling Pathway in Human Cancer , 2012, International journal of molecular sciences.

[266]  Jianren Gu,et al.  Transient mTOR Inhibition Facilitates Continuous Growth of Liver Tumors by Modulating the Maintenance of CD133+ Cell Populations , 2011, PloS one.

[267]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[268]  Takla Griss,et al.  The Liver Kinase B1 Is a Central Regulator of T Cell Development, Activation, and Metabolism , 2011, The Journal of Immunology.

[269]  Anne E Carpenter,et al.  mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway , 2011, Cell.

[270]  Yang Liu,et al.  The Tuberous Sclerosis Complex–Mammalian Target of Rapamycin Pathway Maintains the Quiescence and Survival of Naive T Cells , 2011, The Journal of Immunology.

[271]  Sarat Chandarlapaty,et al.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.

[272]  C. Burger.  Efficacy and safety of sirolimus in lymphangioleiomyomatosis. , 2011, The New England journal of medicine.

[273]  Aileen McHarg,et al.  PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity , 2011, Molecular Cancer Therapeutics.

[274]  A. F. Castro,et al.  Consequences of interrupted Rheb-to-AMPK feedback signaling in tuberous sclerosis complex and cancer , 2011, Small GTPases.

[275]  D. Green,et al.  Tuberous sclerosis complex 1 (Tsc1) enforces quiescence of naive T cells to promote immune homeostasis and function , 2011, Nature immunology.

[276]  P. Houghton,et al.  Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin , 2011, Molecular Cancer Therapeutics.

[277]  S. Gygi,et al.  Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling , 2011, Science.

[278]  D. Alessi,et al.  Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. , 2011, The Biochemical journal.

[279]  B. Manning,et al.  Transcriptional control of cellular metabolism by mTOR signaling. , 2011, Cancer research.

[280]  M. Höglund,et al.  A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1 , 2011, PloS one.

[281]  D. Sabatini,et al.  The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling , 2011, Science.

[282]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[283]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[284]  L. Feldberg,et al.  Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor , 2011, Clinical Cancer Research.

[285]  C. Parent,et al.  Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. , 2011, Blood.

[286]  K. Tachibana,et al.  Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. , 2010, Neuro-oncology.

[287]  D. Sabatini,et al.  Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. , 2010, Molecular cell.

[288]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[289]  D. Schatz,et al.  Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells. , 2010, Molecular cell.

[290]  Yeo Joon Yoon,et al.  Biosynthesis of rapamycin and its regulation: past achievements and recent progress , 2010, The Journal of Antibiotics.

[291]  Qicheng Ma,et al.  Activation of a metabolic gene regulatory network downstream of mTOR complex 1. , 2010, Molecular cell.

[292]  D. Sabatini,et al.  Structure of the human mTOR complex I and its implications for rapamycin inhibition. , 2010, Molecular cell.

[293]  B. Viollet,et al.  Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. , 2010, Cell metabolism.

[294]  R. Ahmed,et al.  The role of mTOR in memory CD8+ T‐cell differentiation , 2010, Immunological reviews.

[295]  Chang Hwa Jung,et al.  mTOR regulation of autophagy , 2010, FEBS letters.

[296]  Kenneth C. Anderson,et al.  Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma , 2010, Molecular Cancer Therapeutics.

[297]  R. Pazdur,et al.  FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. , 2010, The oncologist.

[298]  Jayanta Debnath,et al.  Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[299]  N. Sonenberg,et al.  Dissecting the role of mTOR: lessons from mTOR inhibitors. , 2010, Biochimica et biophysica acta.

[300]  W. Hörl,et al.  The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[301]  Yang Liu,et al.  mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells , 2009, Science Signaling.

[302]  David K. Finlay,et al.  Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes , 2009, The Journal of experimental medicine.

[303]  D. Sabatini,et al.  mTOR signaling at a glance , 2009, Journal of Cell Science.

[304]  David K. Finlay,et al.  LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells , 2009, European journal of immunology.

[305]  Janet M. Thornton,et al.  Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span , 2009, Science.

[306]  W. Gregory,et al.  Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer , 2009, Clinical Cancer Research.

[307]  N. Saijo,et al.  mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. , 2009, Cancer research.

[308]  She Chen,et al.  ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy* , 2009, Journal of Biological Chemistry.

[309]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[310]  K. Garber.  Targeting mTOR: something old, something new. , 2009, Journal of the National Cancer Institute.

[311]  D. Guertin,et al.  mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.

[312]  P. Schultz,et al.  The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations , 2009, Proceedings of the National Academy of Sciences.

[313]  N. Mizushima,et al.  Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. , 2008, Molecular biology of the cell.

[314]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[315]  T. P. Neufeld,et al.  Regulation of TORC1 by Rag GTPases in nutrient response , 2008, Nature Cell Biology.

[316]  David M. Sabatini,et al.  The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1 , 2008, Science.

[317]  R. Lin,et al.  Rapamycin and mTOR kinase inhibitors , 2008, Journal of chemical biology.

[318]  J. Dipersio,et al.  A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies , 2008, Clinical Cancer Research.

[319]  B. Turk,et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.

[320]  J. Blenis,et al.  SKAR Links Pre-mRNA Splicing to mTOR/S6K1-Mediated Enhanced Translation Efficiency of Spliced mRNAs , 2008, Cell.

[321]  D. Gutmann,et al.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex , 2008, Annals of neurology.

[322]  Daniel J. Klionsky,et al.  Autophagy fights disease through cellular self-digestion , 2008, Nature.

[323]  V. Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[324]  N. Sonenberg,et al.  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. , 2007, Cancer research.

[325]  J. Margolick,et al.  Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance , 2007, Proceedings of the National Academy of Sciences.

[326]  D. Alessi,et al.  Identification of Protor as a novel Rictor-binding component of mTOR complex-2. , 2007, The Biochemical journal.

[327]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[328]  Martin Gore.  Temsirolimus in the treatment of advanced renal cell carcinoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[329]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[330]  D. Sabatini,et al.  Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. , 2007, Blood.

[331]  Hong Wang,et al.  Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. , 2007, American journal of obstetrics and gynecology.

[332]  Seung-Jae V. Lee,et al.  Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans , 2007, Aging cell.

[333]  Michele Pagano,et al.  S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth , 2006, Science.

[334]  K. Inoki,et al.  Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. , 2006, Genes & development.

[335]  Birgit Kasch,et al.  Next Generation , 2005, Im OP.

[336]  Matt Kaeberlein,et al.  Regulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients , 2005, Science.

[337]  D. Longo,et al.  Interleukin-12-induced Interferon-γ Production by Human Peripheral Blood T Cells Is Regulated by Mammalian Target of Rapamycin (mTOR)* , 2005, Journal of Biological Chemistry.

[338]  W. Friedrichs,et al.  Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[339]  Di Chen,et al.  The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span , 2004, Development.

[340]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[341]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[342]  S. Benzer,et al.  Regulation of Lifespan in Drosophila by Modulation of Genes in the TOR Signaling Pathway , 2004, Current Biology.

[343]  A. Hardan,et al.  Topical Review : Neuropsychiatric Problems in Tuberous Sclerosis Complex , 2004 .

[344]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[345]  J. Blenis,et al.  mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E , 2004, Molecular and Cellular Biology.

[346]  Tibor Vellai,et al.  Genetics: Influence of TOR kinase on lifespan in C. elegans , 2003, Nature.

[347]  Amber C. Donahue,et al.  Proliferation and Survival of Activated B Cells Requires Sustained Antigen Receptor Engagement and Phosphoinositide 3-Kinase Activation1 , 2003, The Journal of Immunology.

[348]  S. Sehgal.  Sirolimus: its discovery, biological properties, and mechanism of action. , 2003, Transplantation proceedings.

[349]  Paul Tempst,et al.  GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. , 2003, Molecular cell.

[350]  J. Crespo,et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.

[351]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[352]  R. Schwartz,et al.  Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. , 1999, Journal of immunology.

[353]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[354]  Christine C. Hudson,et al.  Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. , 1997, Science.

[355]  R. Joseph,et al.  A bone collection suction device for use during endosseous implant placement. , 1994, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[356]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION , 1975 .

[357]  S. L. Clark.  CELLULAR DIFFERENTIATION IN THE KIDNEYS OF NEWBORN MICE STUDIED WITH THE ELECTRON MICROSCOPE , 1957, The Journal of biophysical and biochemical cytology.

[358]  Yu Jiang,et al.  mTOR Inhibitors at a Glance. , 2015, Molecular and cellular pharmacology.

[359]  J. Blay,et al.  Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[360]  J. Stockman,et al.  Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis , 2012 .

[361]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[362]  N. Sonenberg,et al.  Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling , 2011 .

[363]  M. Lim,et al.  The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma , 2010, Leukemia.

[364]  Michele Pagano,et al.  S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. , 2006, Science.

[365]  A. Hardan,et al.  Neuropsychiatric problems in tuberous sclerosis complex. , 2004, Journal of child neurology.

[366]  R. Bookstein,et al.  Mutations to CCI-779 PTEN Enhanced Sensitivity of Multiple Myeloma Cells Containing Updated Version , 2002 .

[367]  R. Yatscoff,et al.  Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation. , 2000, Clinical therapeutics.